Eyepoint Pharmaceuticals (EYPT) Competitors

Eyepoint Pharmaceuticals currently has a consensus target price of $44.38, suggesting a potential upside of 200.85%. Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Eyepoint Pharmaceuticals had 21 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 21 mentions for Eyepoint Pharmaceuticals and 0 mentions for Catalyst Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.03 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Eyepoint Pharmaceuticals' return on equity.

Catalyst Pharmaceuticals has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Structure Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Eyepoint Pharmaceuticals had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 21 mentions for Eyepoint Pharmaceuticals and 13 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.04 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Structure Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Structure Therapeutics' return on equity of -26.12% beat Eyepoint Pharmaceuticals' return on equity.

Eyepoint Pharmaceuticals presently has a consensus price target of $44.38, suggesting a potential upside of 200.85%. Structure Therapeutics has a consensus price target of $110.91, suggesting a potential upside of 103.47%. Given Eyepoint Pharmaceuticals' higher possible upside, equities analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Structure Therapeutics.

Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.43, meaning that its share price is 243% less volatile than the broader market.

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 16.88%. Eyepoint Pharmaceuticals has a consensus target price of $44.38, suggesting a potential upside of 200.85%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Organon & Co..

In the previous week, Eyepoint Pharmaceuticals had 14 more articles in the media than Organon & Co.. MarketBeat recorded 21 mentions for Eyepoint Pharmaceuticals and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.92 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Organon & Co. is being referred to more favorably in the media.

Organon & Co. has a net margin of 3.41% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Organon & Co.'s return on equity of 88.97% beat Eyepoint Pharmaceuticals' return on equity.

Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Arcutis Biotherapeutics' return on equity of 15.05% beat Eyepoint Pharmaceuticals' return on equity.

Eyepoint Pharmaceuticals presently has a consensus price target of $44.38, indicating a potential upside of 200.85%. Arcutis Biotherapeutics has a consensus price target of $35.57, indicating a potential upside of 35.82%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Arcutis Biotherapeutics.

Eyepoint Pharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 23 mentions for Arcutis Biotherapeutics and 21 mentions for Eyepoint Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.74 beat Eyepoint Pharmaceuticals' score of 0.03 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.